SCHEMBL13745366

SCHEMBL13745366

Fc1cccc(-c2cnc3[nH]cc(-c4ccoc4)c3c2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 2/20 0.77
CDK2 P24941 4/20 0.60
KIT P10721 2/20 0.60
CCNT1 O60563 2/20 0.60
CCNA2 P20248 2/20 0.60
CDK9 P50750 2/20 0.60
AXL P30530 4/20 0.56
TNIK Q9UKE5 1/20 0.56
CLK4 Q9HAZ1 3/20 0.54
CDC7 O00311 2/20 0.54
ROCK2 O75116 2/20 0.54
PIM1 P11309 2/20 0.54
GSK3B P49841 2/20 0.54
MAP4K4 O95819 1/20 0.54
PRKACA P17612 1/20 0.54
HIPK2 Q9H2X6 1/20 0.54
IRAK4 Q9NWZ3 1/20 0.54
NTRK1 P04629 4/20 0.54
DYRK1A Q13627 3/20 0.52
CLK2 P49760 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8320045 0.90 CDK8 (0.73) CDK8CDK2KITCCNT1CCNA2
SCHEMBL8313393 0.88 CDK8 (0.77) CDK8CDK2KITCCNT1CCNA2
SCHEMBL13745464 0.87 CDK8 (1.00) CDK8CDK2KITCCNT1CCNA2
SCHEMBL8320115 0.87 CDK8 (0.84) CDK8CDK2KITCCNT1CCNA2
SCHEMBL1516669 0.87 CDK8 (0.76) CDK8CDK2KITCCNT1CCNA2
SCHEMBL13745368 0.87 CDK8 (0.76) CDK8CDK2KITCCNT1CCNA2
SCHEMBL8313308 0.87 CDK8 (0.76) CDK8CDK2KITCCNT1CCNA2
SCHEMBL13745955 0.86 CDK8 (0.71) CDK8CDK2KITCCNT1CCNA2
SCHEMBL13745265 0.85 CDK8 (0.70) CDK8CDK2KITCCNT1CCNA2
SCHEMBL13745362 0.85 CDK8 (0.65) CDK8CDK2KITCCNT1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 CDK8 360/4885CDK2 153/4885KIT 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.